Objective To evaluate the changes of platelet aggregation rate and short-term prognosis after the application of colopidgrel with booster doses or replaced by ticagrelor for ACS patients with CYP2C19 medium-metabolized genotype). Method A total of 302 patients with medium-metabolized genotype were randomly divided into colopidgrel group (75 mg/bid) and ticagrelor group (90 mg/bid). Patients in both groups accepted other conventional treatments of coronary heart disease and accompanied diseases. The platelet aggregation rates and platelet inhibition rates were observed before and after the treatment. The incidence of adverse events was followed up within 1 m. Results After one-week treatment, the platelet aggregation rates of the inducement with 5 μmol/L ADP had statistical significance between colopidgrel group and ticagrelor group ( P = 0 . 019 ) and the platelet inhibition rates had statistical significance difference between the two groups (P = 0.000). No severe adverse events occurred within one-month follow-up and 10 dyspnea patients were all in ticagrelor group. Conclusions Compared with booster doses of clopidogrel, ticagrelor presents obvious inhibitory effect on platelet of patients with medium-metabolized of ACS but it increases the incidence of dyspnea.%目的：评价CYP2C19中等代谢型的急性冠脉综合征（ACS）患者，加量应用氯吡格雷或换用替格瑞洛血小板聚集率变化以及短期预后。方法：选取CYP2C19中间代谢型ACS患者302例随机分为氯吡格雷组（75 mg／bid）和替格瑞洛组（90 mg／bid）。观察治疗1周前、后血小板聚集率、血小板抑制率。并随访1个月内不良事件。结果：中间代谢型ACS患者治疗1周后，氯吡格雷组血小板聚集率显著高于替格瑞洛组（P ＝0．019），氯吡格雷组血小板抑制率显著低于替格瑞洛组（P ＝0．000）。1个月随访发现，两组均无严重心脑血管事件发生。呼吸困难10例均发生在替格瑞洛组。结论：与加量应用氯吡格雷相比，CYP2C19中代谢型的ACS患者应用替格瑞洛较加量应用氯吡格雷对血小板的抑制作用更强，但增加呼吸困难的发生率。
展开▼
